Skip to main content

Table 2 Comparison of OCT baseline characteristics and outcome measures between functional responders and non-responders. Baseline, 3 months and 6 months of follow-up in eyes with DME treated with anti-VEGF agents

From: Evaluation of markers of outcome in real-world treatment of diabetic macular edema

 

Functional non-responders (N = 26)

Early functional responders (N = 74)

Late functional responders (N = 22)

p-valuea

p-valueb

BCVA (L)

 Baseline

65.3 ± 10.5

62.3 ± 13.2

63.8 ± 13.4

0.535

0.447

 3 M

63.9 ± 13.4

72.2 ± 11.0

65.1 ± 12.6

0.009

0.001

p-value 3 M

0.506

< 0.001

0.13

  

 6 M

64.7 ± 12.0

75.5 ± 9.6

72.7 ± 11.8

< 0.001

< 0.001

 p-value 6 M

0.847

< 0.001

< 0.001

  

CRT (μm)

 Baseline

420.7 ± 99.1

435.8 ± 109.5

434.9 ± 111.1

0.563

0.553

 3 M

346.9 ± 90.3

334.4 ± 62.0

348.3 ± 86.7

0.712

0.792

 p-value 3 M

< 0.001

< 0.001

< 0.001

  

 6 M

370.4 ± 111.4

332.3 ± 61.5

311.7 ± 44.4

0.455

0.460

p-value 6 M

0.001

< 0.001

< 0.001

  

SFCT (μm)

 Baseline

339.3 ± 63.4

343.7 ± 82.6

365.3 ± 62.5

0.532

0.783

 3 M

328.2 ± 71.9

319.3 ± 76.2

335.4 ± 57.5

0.746

0.597

p-value 3 M

0.061

< 0.001

0.003

  

 6 M

303.6 ± 66.4

326.9 ± 83.2

321.7 ± 66.2

0.156

0.157

p-value 6 M

< 0.001

0.001

< 0.001

  

Baseline SND

 Yes

3 (11.5%)

21 (28.4%)

3 (13.6%)

0.187

0.111

 No

23 (88.5%)

53 (71.6%)

19 (86.4%)

  

Baseline EZ

 Intact

13 (50.0%)

54 (72.9%)

13 (59.1%)

0.063

0.030

 Disrupted

13 (50.0%)

19 (25.7%)c

9 (40.9%)

  

3 M EZ

 Intact

12 (46.2%)

62 (83.8%)

15 (68.2%)

0.001

< 0.001

 Disrupted

14 (53.8%)

12 (16.2%)

7 (31.8%)

  

Laser

 Yes

22 (84.6%)

36 (48.6%)

10 (45.5%)

< 0.001

0.001

 No

4 (15.4%)

38 (51.4%)

12 (54.5%)

  

Number of Injections

4.4 ± 1.3

4.7 ± 1.3

4.8 ± 1.3

0.267

0.334

  1. Abbreviations: BCVA=best corrected visual acuity scored using the ETDRS letters (L) chart, ETDRS 62 L are Snellen 20/58, 64 L (20/53), 65 L (20/50), 72 L (20/36), 73 L (20/35) and 76 L (20/30); 3M=3-month endpoint after the loading dose; 6 M=6-month endpoint; CRT=1 mm central retinal thickness; SFCT=subfoveal choroidal thickness; SND=subfoveal neuroretinal detachment; EZ=ellipsoid zone; 3 M EZ=re-rating of the ellipsoid zone after the loading dose
  2. Number of injections is the mean number of injections given until 6 M
  3. aComparing responders vs. non-responders
  4. bComparing early responders vs. non-responders
  5. cOne eye with unreadable EZ. BCVA increased significantly only in functional responders. CRT and SFCT changes from baseline do not show a statistically significant difference between responders and non-responders displaying the poor correlation between functional response and anatomic response. An intact EZ at baseline was present in a higher proportion among functional responders and that was even more significant with the 3 M re-rating. Laser naivety was more commonly found in functional responders